Immuneering Corp Stock Alpha and Beta Analysis
| IMRX Stock | USD 1.60 0.06 3.90% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Immuneering Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Immuneering Corp over a specified time horizon. Remember, high Immuneering Corp's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Immuneering Corp's market risk premium analysis include:
Beta 0.74 | Alpha (0.28) | Risk 4.5 | Sharpe Ratio (0.01) | Expected Return (0.03) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Immuneering |
Immuneering Corp Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Immuneering Corp market risk premium is the additional return an investor will receive from holding Immuneering Corp long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immuneering Corp. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Immuneering Corp's performance over market.| α | -0.28 | β | 0.74 |
Immuneering Corp expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Immuneering Corp's Buy-and-hold return. Our buy-and-hold chart shows how Immuneering Corp performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Immuneering Corp Market Price Analysis
Market price analysis indicators help investors to evaluate how Immuneering Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Immuneering Corp shares will generate the highest return on investment. By understating and applying Immuneering Corp stock market price indicators, traders can identify Immuneering Corp position entry and exit signals to maximize returns.
Immuneering Corp Return and Market Media
The median price of Immuneering Corp for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 1.91 with a coefficient of variation of 13.05. The daily time series for the period is distributed with a sample standard deviation of 0.25, arithmetic mean of 1.9, and mean deviation of 0.2. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Immuneering Launches Pancreatic Cancer Advisory Board | 12/19/2024 |
2 | Acquisition by Keating Laurie of 23485 shares of Immuneering Corp at 2.2 subject to Rule 16b-3 | 12/31/2024 |
3 | Immuneering Corp reports promising clinical trial data | 01/07/2025 |
4 | Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with ... | 01/13/2025 |
5 | Immuneering Leads The Pack Of 3 US Penny Stocks To Consider | 01/23/2025 |
6 | Acquisition by Bookman Michael of 110000 shares of Immuneering Corp at 1.91 subject to Rule 16b-3 | 02/05/2025 |
7 | Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo | 02/06/2025 |
8 | Immuneering Co. Given Consensus Recommendation of Hold by Brokerages | 02/10/2025 |
9 | Acquisition by Schall Thomas J. of 8588 shares of Immuneering Corp at 1.54 subject to Rule 16b-3 | 02/27/2025 |
10 | Immuneering Slides As Insider Purchases Lose Another US186k | 03/05/2025 |
11 | Acquisition by Berman Ann E of 17614 shares of Immuneering Corp at 2.2 subject to Rule 16b-3 | 03/07/2025 |
12 | Acquisition by Brett Hall of 6211 shares of Immuneering Corp at 1.62 subject to Rule 16b-3 | 03/12/2025 |
About Immuneering Corp Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Immuneering or other stocks. Alpha measures the amount that position in Immuneering Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.42 | 0.4 | Days Of Inventory On Hand | 0.002078 | 0.001846 |
Immuneering Corp Upcoming Company Events
As portrayed in its financial statements, the presentation of Immuneering Corp's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immuneering Corp's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Immuneering Corp's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Immuneering Corp. Please utilize our Beneish M Score to check the likelihood of Immuneering Corp's management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Immuneering Corp
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.